Have a feature idea you'd love to see implemented?
Let us know!
LRMR Larimar Therapeutics Inc
Price (delayed)
$6.13
Market cap
$391.13M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.14
Enterprise value
$360.09M
Larimar Therapeutics, Inc., is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company's lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical
Highlights
The debt has contracted by 4.2% from the previous quarter
LRMR's equity has surged by 114% year-on-year but it is down by 6% since the previous quarter
LRMR's quick ratio is up by 17% since the previous quarter but it is down by 15% year-on-year
The company's net income has shrunk by 94% YoY and by 11% QoQ
The EPS has plunged by 90% YoY and by 2.7% from the previous quarter
Key stats
What are the main financial stats of LRMR
Market
Valuations
Earnings
Shares outstanding
63.81M
Market cap
$391.13M
Enterprise value
$360.09M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.97
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$64.77M
EBITDA
-$64.61M
Free cash flow
-$58.79M
Per share
Balance sheet
Liquidity
EPS
-$1.14
Free cash flow per share
-$0.92
Book value per share
$3.11
Revenue per share
$0
TBVPS
$3.43
Total assets
$219.02M
Total liabilities
$20.62M
Debt
$5.36M
Equity
$198.4M
Working capital
$196.97M
Debt to equity
0.03
Current ratio
13.1
Quick ratio
12.59
Net debt/EBITDA
0.48
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-32.4%
Return on equity
-35.9%
Return on invested capital
-46.9%
Return on capital employed
-31.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LRMR stock price
How has the Larimar Therapeutics stock price performed over time
Intraday
0.82%
1 week
-19.02%
1 month
-18.59%
1 year
99.03%
YTD
34.73%
QTD
-6.41%
Financial performance
How have Larimar Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$73.76M
Net income
-$64.77M
Gross margin
N/A
Net margin
N/A
The company's net income has shrunk by 94% YoY and by 11% QoQ
Larimar Therapeutics's operating income has shrunk by 94% YoY and by 12% QoQ
Growth
What is Larimar Therapeutics's growth rate over time
Valuation
What is Larimar Therapeutics stock price valuation
P/E
N/A
P/B
1.97
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has plunged by 90% YoY and by 2.7% from the previous quarter
LRMR's equity has surged by 114% year-on-year but it is down by 6% since the previous quarter
LRMR's P/B is 10% below its last 4 quarters average of 2.2 but 3.7% above its 5-year quarterly average of 1.9
Efficiency
How efficient is Larimar Therapeutics business performance
The ROIC has grown by 39% YoY and by 11% from the previous quarter
Larimar Therapeutics's ROA has decreased by 12% YoY but it has increased by 5% from the previous quarter
LRMR's ROE is down by 10% year-on-year but it is up by 5% since the previous quarter
Dividends
What is LRMR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LRMR.
Financial health
How did Larimar Therapeutics financials performed over time
The total assets has soared by 111% YoY but it is down by 8% QoQ
LRMR's total liabilities has surged by 83% year-on-year but it is down by 20% since the previous quarter
The debt is 97% less than the equity
LRMR's equity has surged by 114% year-on-year but it is down by 6% since the previous quarter
LRMR's debt to equity has plunged by 50% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.